HEMATOLOGY

An application for approval of a new dosing schedule of Rylaze has been submitted to the FDA.

With a partial clinical hold placed by the FDA, all studies of magrolimab plus azacitidine must halt screening and enrollment.

For the treatment of patients with myelodysplastic syndrome, the FDA has granted an orphan drug designation to eltanexor.

A phase 2b study aims to confirm positive efficacy and safety results previously reported with the combination of maveropepimut-S and pembrolizumab in patients with relapsed or refractory diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Ronald S. Go, MD, discussed the new guidelines for the diagnosis and treatment of histiocytic neoplasms, challenges with managing the disease, and toxicity management.

Twenty-two days following transplantation, a patient with graft-versus-host disease presented with new symptoms.

Patients with high levels of amphiregulin appeared to be at a higher risk of early death from acute graft-versus-host-disease, signaling that it may be a predictive biomarker.

Although cytokine release syndrome can occur in patients treated with APVO436, the event can be managed with steroids without adversely affecting treatment.

John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.

An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.

John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.

A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.

John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.

A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.

John Allan, MD, presents and reviews the case of a 67-year-old man with chronic lymphocytic leukemia.

In the MEDALIST analysis that was presented at the 2021 ASH Annual Meeting, investigators sought to further characterize the effects of luspatercept in patients with low-risk myelodysplastic syndrome.

High antibody levels were observed in patients with acute myeloid leukemia and myelodysplastic syndrome who received the mRNA-1273 SARS CoV-2 vaccination.

Combining daratumumab with bortezomib, cyclophosphamide, and dexamethasone improved hematologic and organ responses after 18 months of follow-up in the phase 3 ANDROMEDA study.

Luspatercept-aamt for the treatment of anemia in adult patients with non-transfusion dependent beta thalassemia is on track to receive an FDA approval indication.

A novel chimeric antigen receptor T-cell agent will now be developed in the United States following an orphan drug designation granted by the FDA.

The newly accepted FDA approval application for betibeglogene autotemcel is supported by 5 studies of the agent across all ages of patients. Eighty-nine percent of evaluable patients achieved transfusion independence.

Ronald S. Go, MD, a hematology oncologist with the Mayo Clinic, discusses treating and diagnosing histiocytic neoplasms, a rare hematologic cancer.

Jeffrey Miller, MD, discusses the background of the Tri-Specific Killer Engager TRICK platform for the activation of natural killer cells for the treatment of refractory tumors, including those that are hematology-based.

Complex challenges have arisen with classifying and treating hematologic malignancies in recent years, according to Jorge E. Cortes, MD.

Rachel B. Salit, MD, discussed the case of a 48-year-old patient with graft-versus-host-disease.